# Follicular Lymphoma (FL) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/follicular-lymphoma-fl

> 8 upcoming FDA catalysts in follicular Lymphoma (FL): Ordspono™ (odronextamab, REGN) on Feb to May 2028 (topline data readout); Ordspono™ (odronextamab, REGN) on February 2028 (primary completion); tisagenlecleucel (NVS) on Jul to Oct 2028 (topline data readout); tisagenlecleucel (NVS) on July 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2028 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091254)) |
| February 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091254)) |
| Jul to Oct 2028 | [Tisagenlecleucel topline data readout](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | Follicular Lymphoma (FL) | scheduled | "NCT05888493 (A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888493)) |
| July 2028 | [Tisagenlecleucel primary completion](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | Follicular Lymphoma (FL) | scheduled | "NCT05888493 (A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888493)) |
| Jul to Oct 2029 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097364)) |
| July 2029 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097364)) |
| December 2029 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Follicular Lymphoma (FL) | scheduled | "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05409066)) |
| Dec 2029 to Mar 2030 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Follicular Lymphoma (FL) | scheduled | "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05409066)) |

## Drugs

- [Ordspono™ (odronextamab)](https://sec-api.dev/pdufa/odronextamab) (REGN)
- [Tisagenlecleucel](https://sec-api.dev/pdufa/tisagenlecleucel) (NVS)
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/follicular-lymphoma-fl.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Follicular Lymphoma (FL) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/follicular-lymphoma-fl

```bibtex
@misc{secapidev_indications_follicular_lymphoma_fl_20261116,
  title        = {Follicular Lymphoma (FL) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/follicular-lymphoma-fl}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_follicular_lymphoma_fl_20261116","title":"Follicular Lymphoma (FL) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/follicular-lymphoma-fl","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
